Cervical Intraepithelial Neoplasia Grade 2/3 Clinical Trial
Official title:
A Feasibility Trial of Alternating Intravaginal Application of 5-Fluorouracil and Imiquimod for Treatment of High-Grade Cervical Squamous Intraepithelial Lesions
This early phase I clinical trial studies the side effects of topical fluorouracil and imiquimod ointment in treating patients with high-grade cervical intraepithelial neoplasia. Topical fluorouracil may kill precancerous cells. Imiquimod ointment may stimulate the immune system. Applying topical fluorouracil and imiquimod ointment may cause fewer side effects and may be a better way to treat patients with precancerous cervical lesions.
PRIMARY OBJECTIVE: I. Assess feasibility, evaluated based on safety and tolerability, of a combination agent intervention (once-weekly self-administered intravaginal application of 5-fluorouracil alternating with once-weekly provider-applied imiquimod) for treatment of high-grade cervical squamous intraepithelial lesions. SECONDARY OBJECTIVES: I. Assess efficacy of the combination agent intervention on cervical disease regression (endpoint based on histologic regression from high-grade lesions to low-grade or no lesions and clearance of high risk-human papillomavirus [HPV] detection) between baseline and study exit visits. II. Assess efficacy of the combination agent intervention on genotype-specific HPV clearance between baseline and study exit visits. III. Assess efficacy of the combination agent intervention on biomarkers of local immune activation (measurement of changes in expression of Toll-like receptors (TLR) and T-regulatory cells and the levels of innate, immune mediating and proinflammatory cytokines with intravaginal 5-fluorouracil [FU] and imiquimod) between baseline and study exit visits. OUTLINE: This is a phase I, dose escalation study of imiquimod. Patients receive topical fluorouracil intravaginally via applicator at weeks 1, 3, 5, 7, 9, 11, 13, and 15 and imiquimod intravaginally via applicator at weeks 2, 4, 6, 8, 10, 12, 14, and 16. Patients who are menstruating will delay application until the end of the menstrual cycle. After completion of study treatment, patients are followed up within 8 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04484415 -
Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)
|
Phase 3 | |
| Not yet recruiting |
NCT06258564 -
The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization
|
||
| Recruiting |
NCT04788849 -
Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples
|
||
| Not yet recruiting |
NCT06273553 -
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02149030 -
Effectiveness of Cervical Screening in HPV Vaccinated Women
|
Phase 4 | |
| Completed |
NCT01550783 -
Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening
|
N/A | |
| Enrolling by invitation |
NCT04755517 -
Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)
|
N/A | |
| Completed |
NCT02811367 -
The HPV Self-test as a Test of Cure in Madagascar
|
N/A | |
| Completed |
NCT00081263 -
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
|
Phase 2 | |
| Recruiting |
NCT05405270 -
Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment
|
||
| Completed |
NCT04312737 -
Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
|
||
| Completed |
NCT02067468 -
Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia
|
N/A | |
| Completed |
NCT02354534 -
Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
|
Phase 1 | |
| Recruiting |
NCT03366493 -
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection
|
Phase 3 | |
| Active, not recruiting |
NCT03064087 -
Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples
|
||
| Recruiting |
NCT05851079 -
Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions
|
||
| Recruiting |
NCT03274206 -
A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)
|
Phase 2 |